6/28/23, 12:49 AM AVERT Pathway Feedback Search Clinical Topics Home Studies AVERT AVERT Disease Disease Deep vein thrombosis Pulmonary embolism Trial question What is the effect of thromboprophylaxis with apixaban in intermediate-to-high-risk ambulatory patients with cancer who were starting chemotherapy? Study design Multi-center Double blinded RCT Population Characteristics of study participants 57.0% female N = 563 43.0% male 563 patients (323 female, 240 male) Inclusion criteria: ambulatory patients with cancer who were at intermediate-to-high risk for VTE and were initiating chemotherapy Key exclusion criteria: increased risk for clinically significant bleeding, hepatic disease associated with coagulopathy, basal cell carcinoma, SCC, acute leukemia, myeloproliferative neoplasm, stem cell transplantation Interventions N=288 apixaban (2.5 mg BID for 180 days) N=275 placebo (identical tablets BID for 180 days) https://web.pathway.md/studies/recmFevGXOdL9VuoM 1/2 6/28/23, 12:49 AM AVERT Pathway Primary outcome Rate of venous thromboembolism within 180 days 10.2 % 10.2 7.6 % 5.1 % 4.2 Significant decrease 2.5 % NNT = 17 0.0 % Apixaban Placebo Significant decrease in the rate of VTE within 180 days (4.2% vs. 10.2%; HR 0.41, 95% CI 0.26 to 0.65) Secondary outcomes Significant increase in major bleeding in modified intention-to-treat analysis (3.5% vs. 1.8%; HR 2, 95% CI 1.01 to 3.95) Safety outcomes No significant differences in major bleeding during treatment period (2.1% vs. 1.1%; HR 1.89, 95% CI 0.39-9.24). Conclusion In ambulatory patients with cancer who were at intermediate-to-high risk for VTE and were initiating chemotherapy, apixaban was superior to placebo with respect to the rate of VTE within 180 days. Reference Carrier M, Abou-Nassar K, Mallick R et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):711-719. Open reference URL https://web.pathway.md/studies/recmFevGXOdL9VuoM 2/2